Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
MARINUS PHARMACEUTICALS, INC. (MRNS) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/13/2019 8-K Appointed a new director
Docs: "Certificate of Designations, Preferences and Rights of Series A Participating Convertible Preferred Stock",
"Press Release",
"Marinus Pharmaceuticals Announces closing of $70 million Public Offering of Common Stock AND CONCURRENT PRIVATE PLACEMENT INCLUDING full exercise of underwriters’ option to purchase additional shares"
09/05/2018 8-K Appointed a new director
Docs: "Marinus Appoints Scott Braunstein, MD to its Board of Directors RADNOR, PA, September 5, 2018 — Marinus Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Dr. Scott Braunstein to its Board of Directors. “We are excited to have Dr. Braunstein join our Board,” commented Christopher M. Cashman, chief executive officer of Marinus Pharmaceuticals. “Dr. Braunstein is well-known in the healthcare industry for his successful track record as an investor and for providing strategic and organizational expertise in various operational roles. Drawing on his knowledge of Wall Street and strategic guidance, Scott will provide fresh insights as Marinus advances its ..."
02/01/2017 8-K Form 8-K - Current report
09/07/2016 8-K Appointed a new director
Docs: "Marinus Appoints Seth H.Z. Fischer to its Board of Directors RADNOR, PA, September 7, 2016 — Marinus Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Seth H.Z. Fischer to its Board of Directors. “Seth brings over 30 years of pharmaceutical operations and commercialization experience,” stated Christopher M. Cashman, chairman and chief executive officer of Marinus Pharmaceuticals. “Seth has successfully advanced and commercialized a wide range of therapeutics, including Topamax® in epilepsy and migraines. We will look to leverage his significant knowledge as we advance ganaxolone in status epilepticus and rare pediatric genetic indications. I join my..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy